glp-1 obesity drug news updates Agonists Weight Loss Drugs Market Report, 2025-2030 Fmr. FDA Commissioner weighs in

This infographic breaks down these drugs by active ingredients, brand names and approved uses of popular GLP-1s.

Liraglutide (3.0 mg, daily subcutaneous injection, n=22) or semaglutide (1.0 mg, weekly subcutaneous injection, n=18) was started 74.5 (51.0, 108.3) months after surgery following a weight regain of 14.7 (10.3, 19.6)%

To read more in detail (and explore the research further):

Bundle Features

The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023

Providers on our platform can now send prescriptions for Zepbound vials and KwikPen, as well as Foundayo, to the LillyDirect pharmacy and access self-pay pricing for Hims & Hers customers.